21. ミトコンドリア病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 39 / 薬物数 : 42 - (DrugBank : 32) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 67
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
A042917017
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Alpha-tocotrienol quinone
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Bupropion
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Caffeine
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
CoenzymeQ10
University of Florida
2007 Phase 3 NCT00432744 Canada;United States;
Creatine
Children's Hospital of Philadelphia
2021 - NCT04734626 United States;
Cysteamine Bitartrate
Horizon Pharma USA, Inc.
2015 Phase 2 NCT02473445 United States;
2014 Phase 2 NCT02023866 United States;
Dexmedetomidine
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
Dextromethorphan
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
EPI-743
National Human Genome Research Institute (NHGRI)
2012 Phase 1/Phase 2 NCT01642056 United States;
EPI743
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Elamipretide
Stealth BioTherapeutics Inc.
2022 Phase 3 NCT05162768 United States;
2016 Phase 2 NCT02976038 United States;
2016 Phase 2 NCT02805790 United States;
Elamipretide (high dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Elamipretide (intermediate dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Elamipretide (low dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Feburane
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Flurbiprofen
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Fluzone®
Stanford University
2010 Phase 4 NCT01831934 United States;
KH176
Khondrion B.V.
2021 Phase 2 EUCTR2020-003124-16-NL Netherlands;
Khondrion BV
2016 Phase 2 NCT02909400 Netherlands;
2016 Phase 2 EUCTR2016-001696-79-NL Netherlands;
2015 Phase 1 NCT02544217 Belgium;
KL1333
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
2019 Phase 1 NCT03888716 United Kingdom;
Low Residue Diet Intervention
Newcastle University
2017 - NCT03388528 United Kingdom;
MTP-131
Stealth BioTherapeutics Inc.
2022 Phase 3 EUCTR2021-003907-16-HU Australia;Denmark;Finland;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Midazolam injection
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Omeprazole
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
PTC743
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-IT France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Pheburane
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Propofol
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
RG2133 (2',3',5'-tri-O-acetyluridine)
Repligen Corporation
2003 Phase 1 NCT00060515 United States;
Reagila
Semmelweis University, STIA-POC-2020
2021 Phase 4 EUCTR2021-001268-58-HU Hungary;
Repaglinide
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
SPP-004
Saitama Medical University Hospital
2019 Phase 3 JPRN-JMA-IIA00406 Japan;
2018 Phase 3 JPRN-JMA-IIA00358 Japan;
2015 Phase 2 JPRN-JMA-IIA00214 Japan;
2014 Phase 2 JPRN-JMA-IIA00200 Japan;
Sevoflurane
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
d sessler
2006 - NCT01001585 United States;
Sonlicromanol
Khondrion B.V.
2021 Phase 2 EUCTR2020-003124-16-NL Netherlands;
Khondrion BV
2021 Phase 2 NCT04846036 Netherlands;
Vatiquinone
PTC Therapeutics
2020 Phase 2/Phase 3 NCT04378075 Italy;Spain;United Kingdom;United States;
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Alpha-tocotrienol quinone
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Bupropion
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Caffeine
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
CoenzymeQ10
University of Florida
2007 Phase 3 NCT00432744 Canada;United States;
Creatine
Children's Hospital of Philadelphia
2021 - NCT04734626 United States;
Cysteamine Bitartrate
Horizon Pharma USA, Inc.
2015 Phase 2 NCT02473445 United States;
2014 Phase 2 NCT02023866 United States;
Dexmedetomidine
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
Dextromethorphan
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
EPI-743
National Human Genome Research Institute (NHGRI)
2012 Phase 1/Phase 2 NCT01642056 United States;
EPI743
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Elamipretide
Stealth BioTherapeutics Inc.
2022 Phase 3 NCT05162768 United States;
2016 Phase 2 NCT02976038 United States;
2016 Phase 2 NCT02805790 United States;
Elamipretide (high dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Elamipretide (intermediate dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Elamipretide (low dose)
Stealth BioTherapeutics Inc.
2015 Phase 1/Phase 2 NCT02367014 United States;
Feburane
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Flurbiprofen
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Fluzone®
Stanford University
2010 Phase 4 NCT01831934 United States;
KH176
Khondrion B.V.
2021 Phase 2 EUCTR2020-003124-16-NL Netherlands;
Khondrion BV
2016 Phase 2 NCT02909400 Netherlands;
2016 Phase 2 EUCTR2016-001696-79-NL Netherlands;
2015 Phase 1 NCT02544217 Belgium;
KL1333
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
2019 Phase 1 NCT03888716 United Kingdom;
Low Residue Diet Intervention
Newcastle University
2017 - NCT03388528 United Kingdom;
MTP-131
Stealth BioTherapeutics Inc.
2022 Phase 3 EUCTR2021-003907-16-HU Australia;Denmark;Finland;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Midazolam injection
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
Omeprazole
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
PTC743
PTC THERAPEUTICS INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-IT France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
PTC THERAPEUTICS, INC.
2021 Phase 2;Phase 3 EUCTR2020-002100-39-ES France;Germany;Italy;Spain;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-SE Australia;Canada;France;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2020-002100-39-FR France;Germany;Italy;Spain;United Kingdom;United States;
Pheburane
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2019 Phase 2 EUCTR2018-001094-25-IT Italy;
Propofol
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
RG2133 (2',3',5'-tri-O-acetyluridine)
Repligen Corporation
2003 Phase 1 NCT00060515 United States;
Reagila
Semmelweis University, STIA-POC-2020
2021 Phase 4 EUCTR2021-001268-58-HU Hungary;
Repaglinide
Abliva AB
2020 Phase 1 NCT04643249 United Kingdom;
SPP-004
Saitama Medical University Hospital
2019 Phase 3 JPRN-JMA-IIA00406 Japan;
2018 Phase 3 JPRN-JMA-IIA00358 Japan;
2015 Phase 2 JPRN-JMA-IIA00214 Japan;
2014 Phase 2 JPRN-JMA-IIA00200 Japan;
Sevoflurane
The University of Texas Health Science Center, Houston
2014 - NCT02053766 United States;
d sessler
2006 - NCT01001585 United States;
Sonlicromanol
Khondrion B.V.
2021 Phase 2 EUCTR2020-003124-16-NL Netherlands;
Khondrion BV
2021 Phase 2 NCT04846036 Netherlands;
Vatiquinone
PTC Therapeutics
2020 Phase 2/Phase 3 NCT04378075 Italy;Spain;United Kingdom;United States;